A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2002
The purpose of this study is to determine whether BMS-188667 will decrease multiple sclerosis disease activity on MRI examinations, as well as decrease the rate of clinical MS exacerbations, compared to placebo
Epistemonikos ID: 80451492321db6ca2d6e9f034e6bcf1c552a6df5
First added on: Mar 31, 2022